NASDAQ · ZNTL
Healthcare · Biotechnology
$3.88
Down-$0.01 (-0.26%)
Updated Aug 28, 2026, 12:59 PM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ZNTL closed at $3.88 after 21 trading sessions, down 21.14% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $3.87 | $3.92 | $3.82 | $3.88 | 430.1K |
| Aug 26, 2026 | $3.87 | $3.93 | $3.83 | $3.89 | 576.21K |
| Aug 25, 2026 | $3.78 | $3.89 | $3.78 | $3.88 | 799.15K |
| Aug 24, 2026 | $3.84 | $3.96 | $3.75 | $3.76 | 988.68K |
| Aug 21, 2026 | $3.95 | $3.95 | $3.815 | $3.825 | 741.8K |
| Aug 20, 2026 | $4.015 | $4.04 | $3.78 | $3.84 | 1.57M |
| Aug 19, 2026 | $3.76 | $3.86 | $3.66 | $3.82 | 1.78M |
| Aug 18, 2026 | $3.75 | $3.86 | $3.58 | $3.68 | 1.2M |
| Aug 17, 2026 | $3.56 | $3.845 | $3.54 | $3.705 | 1.57M |
| Aug 14, 2026 | $3.53 | $3.70 | $3.49 | $3.56 | 4.58M |
| Aug 13, 2026 | $4.29 | $4.42 | $4.135 | $4.15 | 820.21K |
| Aug 12, 2026 | $4.13 | $4.31 | $4.08 | $4.29 | 559.03K |
| Aug 11, 2026 | $4.19 | $4.24 | $4.03 | $4.11 | 401.84K |
| Aug 10, 2026 | $4.20 | $4.28 | $4.04 | $4.15 | 824.76K |
| Aug 7, 2026 | $4.68 | $4.8255 | $4.01 | $4.22 | 1.58M |
| Aug 6, 2026 | $4.92 | $5.15 | $4.92 | $5.00 | 701.82K |
| Aug 5, 2026 | $4.91 | $4.955 | $4.78 | $4.95 | 578.31K |
| Aug 4, 2026 | $4.67 | $4.89 | $4.67 | $4.88 | 788.67K |
| Aug 3, 2026 | $4.79 | $4.89 | $4.619 | $4.65 | 820.5K |
| Jul 31, 2026 | $4.95 | $4.99 | $4.66 | $4.74 | 941.18K |
| Jul 30, 2026 | $4.78 | $5.10 | $4.71 | $4.92 | 1M |
The latest Smart Investors Daily articles mentioning ZNTL.
ZNTL research
Company profile and research snapshot.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 23, 2026 | Rodman & Renshaw | Buy | — |
| Jul 17, 2026 | Mizuho | Outperform | — |
| Apr 10, 2026 | Guggenheim | Buy | — |
| Mar 27, 2026 | Guggenheim | Buy | — |
| Nov 12, 2025 | Morgan Stanley | Equal-Weight | — |
No generated briefing is available yet.
Benzinga · Aug 13, 2026
All of the securities to be sold in the proposed offering will be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares
Benzinga · Jul 23, 2026
Rodman & Renshaw initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy rating and announces Price Target of $11.
Benzinga · Jul 17, 2026
US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big gainers: PHOE, SG, TRVI, DCBO, ZNTL, GPRE, SLS, FEIM, TRV, BHVN, KOS, BJRI, MBX.
Benzinga · Jul 17, 2026
Mizuho analyst Graig Suvannavejh initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and announces Price Target of $8.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ZNTL.
